Safety and Efficacy Considerations of Ezetimibe in Myasthenia Gravis

Adverse Muscle Effects

• The FDA label reports that ezetimibe has been associated with myopathy and rhabdomyolysis, both when used alone and in combination with statins, indicating a serious risk of muscle injury. 1
• Commonly observed adverse events with ezetimibe include myalgia and arthralgia, reflecting a propensity for mild to moderate muscle‑related symptoms. 1

Pharmacologic Interaction with Bile Acid Sequestrants

• Bile acid sequestrant agents (e.g., cholestyramine, colesevelam, colestipol) lower cholesterol by binding bile acids in the intestine rather than inhibiting intestinal cholesterol absorption, providing a mechanistically distinct and muscle‑sparing alternative. 1
• To prevent reduced ezetimibe absorption, the drug should be administered at least 2 hours before or 4 hours after a bile acid sequestrant, ensuring adequate bioavailability. 1

Lipid‑Lowering Efficacy of Ezetimibe

• Clinical evidence demonstrates that ezetimibe achieves an LDL‑C reduction of approximately 18 %– 25 %, contributing to cardiovascular risk mitigation. 1